{"title":"Introduction to MBMA","markdown":{"yaml":{"title":"Introduction to MBMA","description":"The Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) of the Statistics and Pharmacometrics Special Interest group (SxP SIG) held an Introduction to MBMA webinar on 26th January, 2021.","categories":["Webinar","MBMA","MBMA Subgroup"],"date":"2021-01-26","toc":true},"headingText":"Abstract","containsRefs":false,"markdown":"\n\nThe Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) of the Statistics and Pharmacometrics Special Interest group (SxP SIG) held an **Introduction to MBMA** webinar on 26th January, 2021. It was organized by Marion Bouillon-Pichault and Matt Zierhut of the MBMA subgroup. The webinar enabled attendees to understand what MBMA is and presented some examples showing the impact it can have in drug development and other critical business decisions. It was a very well attended session with over 250 engaged attendees.\n\n\nAs landscapes for the treatment of many diseases have grown increasingly competitive and costs to conduct clinical trials have soared, it is critical to understand the landscape of available treatments, as well as the probability that a specific compound could compete successfully in this market.\n\nModel-based meta-analysis (MBMA) is a tool for integrating prior knowledge, both public and proprietary, and for using it to inform discovery and development decisions. As in traditional meta-analysis, MBMA allows one to more precisely quantify a treatment effect by incorporating data from multiple studies. Inclusion of model parameters further enables quantification and explanation of variability observed across trials by accounting for differences in effect modifiers, such as treatments, doses, time, population characteristics, etc. Thus, MBMA is a powerful tool for predicting new, potentially interesting clinical scenarios through clinical trial simulation. Additionally, applying the MBMA to perform simulations can improve strategic decision-making by projecting the likelihood of achieving differentiable efficacy and/or safety.\n\nThe webinar will enable you to understand what MBMA is and will present some examples showing the impact it can have in drug development and other critical business decisions.\n\n<iframe width=\"90%\" height=\"315\" src=\"https://www.youtube.com/embed/bf7_-cNjydQ\" frameborder=\"0\" allowfullscreen>\n\n</iframe>\n\n## Q & A\n\n[Link to the Q & A](https://www.dropbox.com/s/macfdjal49h1ynk/Q%26A%20for%20MBMA.pdf?dl=0)\n","srcMarkdownNoYaml":"\n\nThe Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) of the Statistics and Pharmacometrics Special Interest group (SxP SIG) held an **Introduction to MBMA** webinar on 26th January, 2021. It was organized by Marion Bouillon-Pichault and Matt Zierhut of the MBMA subgroup. The webinar enabled attendees to understand what MBMA is and presented some examples showing the impact it can have in drug development and other critical business decisions. It was a very well attended session with over 250 engaged attendees.\n\n## Abstract\n\nAs landscapes for the treatment of many diseases have grown increasingly competitive and costs to conduct clinical trials have soared, it is critical to understand the landscape of available treatments, as well as the probability that a specific compound could compete successfully in this market.\n\nModel-based meta-analysis (MBMA) is a tool for integrating prior knowledge, both public and proprietary, and for using it to inform discovery and development decisions. As in traditional meta-analysis, MBMA allows one to more precisely quantify a treatment effect by incorporating data from multiple studies. Inclusion of model parameters further enables quantification and explanation of variability observed across trials by accounting for differences in effect modifiers, such as treatments, doses, time, population characteristics, etc. Thus, MBMA is a powerful tool for predicting new, potentially interesting clinical scenarios through clinical trial simulation. Additionally, applying the MBMA to perform simulations can improve strategic decision-making by projecting the likelihood of achieving differentiable efficacy and/or safety.\n\nThe webinar will enable you to understand what MBMA is and will present some examples showing the impact it can have in drug development and other critical business decisions.\n\n<iframe width=\"90%\" height=\"315\" src=\"https://www.youtube.com/embed/bf7_-cNjydQ\" frameborder=\"0\" allowfullscreen>\n\n</iframe>\n\n## Q & A\n\n[Link to the Q & A](https://www.dropbox.com/s/macfdjal49h1ynk/Q%26A%20for%20MBMA.pdf?dl=0)\n"},"formats":{"html":{"identifier":{"display-name":"HTML","target-format":"html","base-format":"html"},"execute":{"fig-width":7,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":false,"echo":true,"output":true,"warning":true,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"engine":"markdown"},"render":{"keep-tex":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":false,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[],"notebook-links":true,"format-links":true},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","to":"html","css":["../../../styles.css"],"toc":true,"output-file":"mbmasubgroup1.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items"},"metadata":{"lang":"en","fig-responsive":true,"quarto-version":"1.3.353","editor":"source","page-layout":"article","theme":"sandstone","title":"Introduction to MBMA","description":"The Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) of the Statistics and Pharmacometrics Special Interest group (SxP SIG) held an Introduction to MBMA webinar on 26th January, 2021.","categories":["Webinar","MBMA","MBMA Subgroup"],"date":"2021-01-26"},"extensions":{"book":{"multiFile":true}}}},"projectFormats":["html"]}